Eli Lilly under pressure as Alzheimer's application delayed

The treatment has hit a stumbling block related to Medicare coverage.

Photo: Mike Blake/REUTERS / X00030

Shares in Eli Lilly dropped by 1.7 percent in value on Thursday, after the leadership team at the US-based pharmaceutical company revealed that their plans to apply for marketing authorization for its Alzheimer’s treatment have been delayed.

According to Bloomberg News, this is because Biogen is struggling to get Medicare coverage for its Alzheimer’s drug, Aduhelm.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs